Loading...
•
Dec 31, 2025
908 Devices Q4 2025 Earnings Report
908 Devices Q4 2025 Earnings Report
Key Takeaways
908 Devices achieved a strong fourth quarter with 21% revenue growth and reached a key milestone of positive Adjusted EBITDA. The company successfully divested its bioprocessing portfolio during the year, focusing resources on health, safety, and defense-tech markets while maintaining a robust cash position of $113 million.
Q4 revenue grew 21% year-over-year to $17.4 million, primarily driven by FTIR product sales.
Achieved positive Adjusted EBITDA of $0.7 million in Q4 2025, compared to a $4.0 million loss in the prior year.
The installed base of devices grew 24% year-over-year to 3,736 units, with 224 devices placed in Q4.
GAAP gross margin improved significantly to 53% in Q4 2025 from 47% in Q4 2024.
Revenue by Segment
Forward Guidance
908 Devices expects continued growth in 2026 following its strategic shift and portfolio optimization.
Positive Outlook
- Full year 2026 revenue expected between $64.5 million and $67.5 million.
- Anticipated annual revenue growth of 15% to 20% compared to 2025.
- Strong balance sheet with $113 million in cash and no debt.
- Growing demand across vital health, safety, and defense-tech markets.
- Improved operating model and expanded margins achieved in late 2025.
Challenges Ahead
- Impact of the divestiture of the bioprocessing product portfolio.
- Ongoing research and development costs required for market expansion.
- Potential volatility in funded partnership revenue timing.
- Macroeconomic factors affecting capital equipment budgets.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...